We believe in sound science as key in our rational, mechanism-based approach of drug discovery. Small molecules interfering with downstream oncogenic signalling represent the recent breakthrough in targeted treatment of chemotherapy-resistant tumours. As molecular markers associated with poor prognosis are increasingly identified, targeted therapies for personalised medicine in a specific subpopulation of patients with refractory disease can be envisioned. HyperSUMOylation is a feature of many resistant cancers and efforts have been initiated by the industry to develop inhibitors of the SUMO E1 enzyme. By science-based rational design, SumiQ is now developing mechanism-based covalent inhibitors of the E1 and E2 enzymes of protein SUMOylation.
UbiQ, one of our founding companies has developed the Triple E platform, published in Nature Chemical Biology (2016), which exploits a reacting group that specifically traps the E1, E2 and E3 ubiquitylating enzymes. By adding this ‘hook’ onto ubiquitin itself or onto a small molecule, it has now, for the first time, become possible to monitor and/or block the activity of dozens of enzymes involved in protein ubiquitylation specifically. SumiQ is now conducting the first program based on this Triple E technology, by developing mechanism-based covalent SUMOylation inhibitors to treat cancer patients.
SumiQ is founded on the joined teams from UbiQ and Mercachem: We combine our expertise in SUMO biology, chemistry, medchem and pre-clinical drug development to deliver proof-of-concept for our innovative targeted antitumour therapy, based on the SUMOylation inhibition.